Investor Narrative V2

MyZenCheck Investor Brief

This page mirrors the full 10-slide investor narrative: vision, problem, product workflow, validation, traction, business model, go-to-market, moat, team, and seed ask.

Language: English Español 中文

Boundary and Compliance Baseline

MyZenCheck is an AI-assisted TCM wellness screening and education platform. It is not a medical device and does not diagnose, treat, cure, or prevent disease.

Headline benchmark: 87.3% practitioner agreement across 881 validation scans.

Slide 1

Vision and Why Now

AI-assisted TCM wellness screening that turns traditional pattern interpretation into accessible, mobile-first, practitioner-aligned insights.

Slide 2

Problem and Access Gap

General apps lack TCM depth; traditional practice has depth but limited digital scale. MyZenCheck closes this gap with non-invasive pattern screening.

Slide 3

Product and Workflow

Capture tongue photo on mobile
Analyze visible features via 7 specialized AI models
Deliver educational TCM pattern context and safe next-step guidance

Slide 4

Validation and Trust Boundaries

87.3% practitioner agreement across 881 validation scans
10,847+ clinically labeled training images
11,000+ scans analyzed as production evidence base
Explicit non-medical boundary in product and content

Slide 5

Traction and Funnel

Product traction is evaluated through conversion, completion, repeat usage, and monetization signals (affiliate and API).

Slide 6

Business Model and Stage Gates

Stage now: B2C acquisition plus practitioner tooling pilots
Stage next: API licensing pilots
Stage expansion: sponsorship and institutional channels

Slide 7

Go-To-Market (12 Months)

Expand validation depth and trust publishing cadence
Improve funnel economics and repeat behavior
Convert paid API pilots into repeatable references
Scale multilingual distribution with claim governance

Slide 8

Moat and Defensibility

Defensibility comes from structured data assets, practitioner-aligned validation process, specialized multi-model workflow, and strict trust governance in a sensitive category.

Slide 9